INFOTEL, INNATE PHARMA, Another 5 Companies Have A High Estimated Dividend Yield

(VIANEWS) – INFOTEL (INF.PA), INNATE PHARMA (IPH.PA), BENFICA (SLBEN.LS) have the highest dividend yield stocks on this list.

Financial Asset Forward Dividend Yield Updated (EST)
INFOTEL (INF.PA) 4.76% 2023-11-10 09:04:50
INNATE PHARMA (IPH.PA) 4.64% 2023-11-10 09:04:51
BENFICA (SLBEN.LS) 3.92% 2023-11-10 08:22:58
TREASURE (TRE.OL) 2.96% 2023-11-09 08:43:51
SOPRA STERIA GROUP (SOP.PA) 2.7% 2023-11-10 09:22:59
WILH. WILHELMSEN B (WWIB.OL) 2.14% 2023-11-10 08:44:14
MEDISTIM (MEDI.OL) 2.08% 2023-11-10 08:41:05

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. INFOTEL (INF.PA)

4.76% Foward Dividend Yield

INFOTEL’s last close was €44.10, 26.25% under its 52-week high of €59.80. Intraday change was 0.45%.

Infotel SA designs, develops, markets, and maintains software solutions in the areas of security, performance, and management worldwide. The company offers Arcsys software solution for electronic archiving of data; and iDBA-Online, an intelligent management solution for administering and maintenance operations for DB2 databases; and Infoscope, a quality application testing. It also provides InfoPak, InfoVic, and InfoUtil software. In addition, the company offers consultancy, analysis, IT system audits, and third-party application maintenance services. It serves banking, finance, insurance/pensions, industry, and administration, as Infotel SA designs, develops, markets, and maintains software solutions in the areas of security, performance, and management worldwide. The company offers Arcsys software solution for electronic archiving of data; and iDBA-Online, an intelligent management solution for administering and maintenance operations for DB2 databases; and Infoscope, a quality application testing. It also provides InfoPak, InfoVic, and InfoUtil software. In addition, the company offers consultancy, analysis, IT system audits, and third-party application maintenance services. It serves banking, finance, insurance/pensions, industry, and administration, as well as services /transport/telecommunication/ distribution sectors. Infotel SA was incorporated in 1979 and is headquartered in Paris, France.ell as services /transport/telecommunication/ distribution sectors. The company was incorporated in 1979 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, INFOTEL has a trailing twelve months EPS of €2.9.

PE Ratio

INFOTEL has a trailing twelve months price to earnings ratio of 15.24. Meaning, the purchaser of the share is investing €15.24 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.4%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.2%, now sitting on 309.64M for the twelve trailing months.

More news about INFOTEL.

2. INNATE PHARMA (IPH.PA)

4.64% Foward Dividend Yield

INNATE PHARMA’s last close was €2.23, 41.45% below its 52-week high of €3.80. Intraday change was -2.16%.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Earnings Per Share

As for profitability, INNATE PHARMA has a trailing twelve months EPS of €-0.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.91%.

Yearly Top and Bottom Value

INNATE PHARMA’s stock is valued at €2.26 at 11:50 EST, way below its 52-week high of €3.80 and way higher than its 52-week low of €1.99.

Revenue Growth

Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 52.28M for the twelve trailing months.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 4.64%.

More news about INNATE PHARMA.

3. BENFICA (SLBEN.LS)

3.92% Foward Dividend Yield

BENFICA’s last close was €3.10, 25.12% under its 52-week high of €4.14. Intraday change was 0.33%.

Sport Lisboa e Benfica – Futebol, SAD operates a sports club in Portugal. The company was founded in 1904 and is headquartered in Lisbon, Portugal. Sport Lisboa e Benfica – Futebol, SAD operates as a subsidiary of Sport Lisboa e Benfica SGPS SA.

Earnings Per Share

As for profitability, BENFICA has a trailing twelve months EPS of €0.18.

PE Ratio

BENFICA has a trailing twelve months price to earnings ratio of 16.72. Meaning, the purchaser of the share is investing €16.72 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.79%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 14.7%, now sitting on 195.8M for the twelve trailing months.

Volume

Today’s last reported volume for BENFICA is 134 which is 90.08% below its average volume of 1351.

More news about BENFICA.

4. TREASURE (TRE.OL)

2.96% Foward Dividend Yield

TREASURE’s last close was kr19.80, 11.61% below its 52-week high of kr22.40. Intraday change was 2.59%.

Treasure ASA, through its 11% interest in Hyundai Glovis Co. Ltd., provides transportation and logistics services in South Korea. The company was incorporated in 2016 and is based in Lysaker, Norway. Treasure ASA is a subsidiary of Wilh. Wilhelmsen Holding ASA.

Earnings Per Share

As for profitability, TREASURE has a trailing twelve months EPS of kr3.43.

PE Ratio

TREASURE has a trailing twelve months price to earnings ratio of 5.77. Meaning, the purchaser of the share is investing kr5.77 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.46%.

More news about TREASURE.

5. SOPRA STERIA GROUP (SOP.PA)

2.7% Foward Dividend Yield

SOPRA STERIA GROUP’s last close was €177.10, 14.86% under its 52-week high of €208.00. Intraday change was -1.17%.

Sopra Steria Group SA provides consulting, digital, and software development services in France and internationally. The company operates through five segments: France, United Kingdom, Other Europe, Sopra Banking Software, and Other Solutions. It offers digital transformation consulting services; technology services in the field of artificial intelligence, blockchain, cloud, data, internet of things, and intelligent process automation; systems integration comprising smart application modernisation and product lifecycle management; infrastructure management services, including consulting, managed and cloud, end-user support, digital workplace, and legacy services; and cybersecurity services. The company also provides property management solutions; banking solutions, including software, support, and associated consulting services to banks and financial institutions; and HR solutions to public and private sector organisations, as well as acts as a software house, integrator, advisor, and cloud player. In addition, it offers business process services, such as creation or on-boarding, and operation of multi-function shared services; and operation of finance and administration, and human resource functions, as well as operation of specialised industry-specific business processes comprising operating and executing services in police control rooms, managing compliance in financial services, and managing customer services for large utilities. It serves aerospace, defense and security, energy and utilities, financial services, insurance and social, government, retail, telecommunication, media and entertainment, and transport industries. Sopra Steria Group SA was incorporated in 1968 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, SOPRA STERIA GROUP has a trailing twelve months EPS of €12.1.

PE Ratio

SOPRA STERIA GROUP has a trailing twelve months price to earnings ratio of 14.64. Meaning, the purchaser of the share is investing €14.64 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.77%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SOPRA STERIA GROUP’s stock is considered to be oversold (<=20).

More news about SOPRA STERIA GROUP.

6. WILH. WILHELMSEN B (WWIB.OL)

2.14% Foward Dividend Yield

WILH. WILHELMSEN B’s last close was kr316.00, 5.33% above its 52-week high of kr300.00. Intraday change was -0.94%.

Wilh. Wilhelmsen Holding ASA provides maritime products and services in Europe, the Oceania, Asia and Africa, and the Americas. It operates through three segments: Maritime Services, New Energy, and Strategic Holdings and Investments. The company offers marine products, including Nalfleet water treatment products to treat and protect on board systems; Unitor chemicals and equipment to clean vessels; Unicool refrigerants; Timm ropes for the maritime industry; Unitor fuel treatment chemicals; Unitor equipment for the maintenance and performance vessels; Unitor cylinders; marine specialty lubricants; and Unitor oil spill equipment and products, and sorbents and booms. It also provides ship agency services to the merchant fleet, as well as ship management services, including manning for various vessels. The company also engages in the operation of supply bases for the offshore industry; development and operation of real estate properties on and off the supply bases; and maintenance of rigs and handling of logistics related to international pipeline projects and windmill parks. Further, it offers technical and crew management services for the offshore wind market, and digital solutions for the shipping industry. Wilh. Wilhelmsen Holding ASA also provides marine and non-marine insurance services; and investment, port, and infrastructure and supply solutions. The company was founded in 1861 and is headquartered in Lysaker, Norway. Wilh. Wilhelmsen Holding ASA is a subsidiary of Tallyman AS.

Earnings Per Share

As for profitability, WILH. WILHELMSEN B has a trailing twelve months EPS of kr110.46.

PE Ratio

WILH. WILHELMSEN B has a trailing twelve months price to earnings ratio of 2.87. Meaning, the purchaser of the share is investing kr2.87 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.7%.

More news about WILH. WILHELMSEN B.

7. MEDISTIM (MEDI.OL)

2.08% Foward Dividend Yield

MEDISTIM’s last close was kr192.00, 38.56% under its 52-week high of kr312.50. Intraday change was 2.56%.

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.42.

PE Ratio

MEDISTIM has a trailing twelve months price to earnings ratio of 31.15. Meaning, the purchaser of the share is investing kr31.15 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.

Yearly Top and Bottom Value

MEDISTIM’s stock is valued at kr200.00 at 11:50 EST, way below its 52-week high of kr312.50 and way above its 52-week low of kr170.50.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be overbought (>=80).

Sales Growth

MEDISTIM’s sales growth is 17.6% for the ongoing quarter and 5.8% for the next.

More news about MEDISTIM.

Leave a Reply

Your email address will not be published. Required fields are marked *